Dovrolis N - Search Results

1

Oral Microbiota as Novel Biomarkers for Colorectal Cancer Screening.

Rezasoltani S, Aghdaei HA, Jasemi S, Gazouli M, Dovrolis N, Sadeghi A, Schlüter H, Zali MR, Sechi LA, Feizabadi MM. Rezasoltani S, et al. Among authors: dovrolis n. Cancers (Basel). 2022 Dec 28;15(1):192. doi: 10.3390/cancers15010192. Cancers (Basel). 2022. PMID: 36612188 Free PMC article.

2

PepServe: a web server for peptide analysis, clustering and visualization.

Alexandridou A, Dovrolis N, Tsangaris GT, Nikita K, Spyrou G. Alexandridou A, et al. Among authors: dovrolis n. Nucleic Acids Res. 2011 Jul;39(Web Server issue):W381-4. doi: 10.1093/nar/gkr318. Epub 2011 May 13. Nucleic Acids Res. 2011. PMID: 21572105 Free PMC article.

3

Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases.

Dovrolis N, Kolios G, Spyrou G, Maroulakou I. Dovrolis N, et al. Drug Discov Today. 2017 May;22(5):805-813. doi: 10.1016/j.drudis.2017.03.009. Epub 2017 Mar 29. Drug Discov Today. 2017. PMID: 28363518 Review.

4

Differential genetic and functional background in inflammatory bowel disease phenotypes of a Greek population: a systems bioinformatics approach.

Gazouli M, Dovrolis N, Franke A, Spyrou GM, Sechi LA, Kolios G. Gazouli M, et al. Among authors: dovrolis n. Gut Pathog. 2019 Jun 15;11:31. doi: 10.1186/s13099-019-0312-y. eCollection 2019. Gut Pathog. 2019. PMID: 31249629 Free PMC article.

5

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases.

Dovrolis N, Michalopoulos G, Theodoropoulos GE, Arvanitidis K, Kolios G, Sechi LA, Eliopoulos AG, Gazouli M. Dovrolis N, et al. Microorganisms. 2020 Mar 20;8(3):438. doi: 10.3390/microorganisms8030438. Microorganisms. 2020. PMID: 32244928 Free PMC article.

6

Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota.

Mavragani CP, Nezos A, Dovrolis N, Andreou NP, Legaki E, Sechi LA, Bamias G, Gazouli M. Mavragani CP, et al. Among authors: dovrolis n. Inflamm Bowel Dis. 2020 Sep 18;26(10):1543-1553. doi: 10.1093/ibd/izaa216. Inflamm Bowel Dis. 2020. PMID: 32812029

7

B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment.

Andreou NP, Legaki E, Dovrolis N, Boyanov N, Georgiou K, Gkouskou K, Gazouli M. Andreou NP, et al. Among authors: dovrolis n. Dig Liver Dis. 2021 May;53(5):574-580. doi: 10.1016/j.dld.2020.11.030. Epub 2020 Dec 16. Dig Liver Dis. 2021. PMID: 33339749

8

miRNAs expression pattern and machine learning models elucidate risk for gastric GIST.

Stefanou IK, Dovrolis N, Gazouli M, Theodorou D, Zografos GK, Toutouzas KG. Stefanou IK, et al. Among authors: dovrolis n. Cancer Biomark. 2022;33(2):237-247. doi: 10.3233/CBM-210173. Cancer Biomark. 2022. PMID: 35213356

9

Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer.

Pliakou E, Lampropoulou DI, Dovrolis N, Chrysikos D, Filippou D, Papadimitriou C, Vezakis A, Aravantinos G, Gazouli M. Pliakou E, et al. Among authors: dovrolis n. Int J Mol Sci. 2022 Dec 20;24(1):46. doi: 10.3390/ijms24010046. Int J Mol Sci. 2022. PMID: 36613487 Free PMC article.

10

Identifying Microbiome Dynamics in Pediatric IBD: More than a Family Matter.

Dovrolis N, Moschoviti A, Fessatou S, Karamanolis G, Kolios G, Gazouli M. Dovrolis N, et al. Biomedicines. 2023 Jul 13;11(7):1979. doi: 10.3390/biomedicines11071979. Biomedicines. 2023. PMID: 37509618 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page